Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Robert Leary"'
Autor:
Janak R. Wedagedera, Anthonia Afuape, Siri Kalyan Chirumamilla, Hiroshi Momiji, Robert Leary, Mike Dunlavey, Richard Matthews, Khaled Abduljalil, Masoud Jamei, Frederic Y. Bois
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 755-765 (2022)
Abstract Physiologically‐based pharmacokinetic (PBPK) models usually include a large number of parameters whose values are obtained using in vitro to in vivo extrapolation. However, such extrapolations can be uncertain and may benefit from inclusio
Externí odkaz:
https://doaj.org/article/b22a6cafc47a40658b0d29adf692a9fc
Autor:
Walter M. Yamada, Michael N. Neely, Jay Bartroff, David S. Bayard, James V. Burke, Mike van Guilder, Roger W. Jelliffe, Alona Kryshchenko, Robert Leary, Tatiana Tatarinova, Alan Schumitzky
Publikováno v:
Pharmaceutics, Vol 13, Iss 1, p 42 (2020)
Population pharmacokinetic (PK) modeling has become a cornerstone of drug development and optimal patient dosing. This approach offers great benefits for datasets with sparse sampling, such as in pediatric patients, and can describe between-patient v
Externí odkaz:
https://doaj.org/article/75ddec7c13e14629b22afaecba91c770
Publikováno v:
IFAC-PapersOnLine. 54:870-875
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95ed9c9675c86add53454d282e0cfb98
https://doi.org/10.1016/j.ifacol.2021.11.281
https://doi.org/10.1016/j.ifacol.2021.11.281
Autor:
Alona Kryshchenko, Michael N. Neely, Jay Bartroff, David S. Bayard, Walter M. Yamada, Tatiana V. Tatarinova, Alan Schumitzky, Roger W. Jelliffe, Mike van Guilder, Robert Leary, James V. Burke
Publikováno v:
Pharmaceutics, Vol 13, Iss 42, p 42 (2021)
Pharmaceutics
Volume 13
Issue 1
Pharmaceutics
Volume 13
Issue 1
Population pharmacokinetic (PK) modeling has become a cornerstone of drug development and optimal patient dosing. This approach offers great benefits for datasets with sparse sampling, such as in pediatric patients, and can describe between-patient v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b64a97328285154a4ec7c3bd0aab71fc
https://doi.org/10.20944/preprints201909.0231.v1
https://doi.org/10.20944/preprints201909.0231.v1
Autor:
Michael Neely, Walter M. Yamada, Tatiana V. Tatarinova, Alan Schumitzky, David S. Bayard, Roger W. Jelliffe, Michael Van Guilder, Robert Leary, Jay Bartroff, Alyona Chubatiuk
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 40:189-199
Population pharmacokinetic (PK) modeling methods can be statistically classified as either parametric or nonparametric (NP). Each classification can be divided into maximum likelihood (ML) or Bayesian (B) approazches. In this paper we discuss the non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e49f5b85a3109400c9337953beff83f1
https://doi.org/10.1007/s10928-013-9302-8
https://doi.org/10.1007/s10928-013-9302-8
Autor:
Roger W. Jelliffe, David S. Bayard, Alan Schumitzky, Aida Bustad, Robert Leary, M. Van Guilder, Andreas Botnen, Michael Neely
Publikováno v:
Current Pharmacogenomics and Personalized Medicine. 7:249-262
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50c070640c462f9c16228150ad5aa039
https://doi.org/10.2174/187569209790112382
https://doi.org/10.2174/187569209790112382
Autor:
Alan Schumitzky, Dimiter Terziivanov, Aida Bustad, Roger W. Jelliffe, Robert Leary, Ruediger E. Port
Publikováno v:
Clinical Pharmacokinetics. 45:365-383
This study examined parametric and nonparametric population modelling methods in three different analyses. The first analysis was of a real, although small, clinical dataset from 17 patients receiving intramuscular amikacin. The second analysis was o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c997387ba688dea86a7776a88be29c50
https://doi.org/10.2165/00003088-200645040-00003
https://doi.org/10.2165/00003088-200645040-00003
Publikováno v:
Antimicrobial agents and chemotherapy. 50(11)
Monte Carlo simulations are increasingly used to predict pharmacokinetic variability of antimicrobials in a population. We investigated the sample size necessary to provide robust pharmacokinetic predictions. To obtain reasonably robust predictions,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a66ec1215f3cb99b571f2e5eb92d3456
https://pubmed.ncbi.nlm.nih.gov/16954312
https://pubmed.ncbi.nlm.nih.gov/16954312
Publikováno v:
Applications of Pharmacokinetic Principles in Drug Development ISBN: 9781461348429
As we acquire experience with the clinical and pharmacokinetic behavior of a drug, it is very desirable to capture this experience and its related information in the form of a population pharmacokinetic model, and then to relate the behavior of the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5f8bf3486c10790d26b6b51a2de9adb
https://doi.org/10.1007/978-1-4419-9216-1_12
https://doi.org/10.1007/978-1-4419-9216-1_12
Autor:
Andreas Botnen, X. Barbaut, Robert Leary, Irina Bondareva, Pascal Maire, Nathalie Bleyzac, Roger W. Jelliffe, Alan Schumitzky, Ashutosh Gandhi
Publikováno v:
Applications of Pharmacokinetic Principles in Drug Development ISBN: 9781461348429
The end product of drug development is the use of the drug in clinical therapy. When a drug has a narrow margin of therapeutic safety, we must steer its dosage between one that is too low, and likely to be ineffective on the one hand, or too high, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb25beafb3fbc2d3cae432fdae9434e3
https://doi.org/10.1007/978-1-4419-9216-1_15
https://doi.org/10.1007/978-1-4419-9216-1_15